Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 19/20 | 0.60 |
| ▸ | ACE | P12821 | 4/20 | 0.60 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086104 | 1.00 | MME (0.60) | MMEACEMMEL1 | |
| SCHEMBL15474326 | 1.00 | MME (0.60) | MMEACEMMEL1 | |
| SCHEMBL18922667 | 0.93 | MME (0.51) | MMEACEMMEL1 | |
| SCHEMBL19688029 | 0.93 | MME (0.51) | MMEACEMMEL1 | |
| SCHEMBL18286815 | 0.93 | MME (0.51) | MMEACEMMEL1 | |
| SCHEMBL24428705 | 0.91 | MME (0.59) | MMEACE | |
| SCHEMBL16942452 | 0.90 | MME (0.48) | MMEACEMMEL1 | |
| SCHEMBL15468044 | 0.90 | MME (0.49) | MMEACEMMEL1 | |
| SCHEMBL19688188 | 0.90 | MME (0.49) | MMEACEMMEL1 | |
| SCHEMBL19376959 | 0.90 | MME (0.49) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-9873685-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-23 | — | — | US | disclosed |
| US-9868698-B2 | (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170355665-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 262/4885 |
| US-20170355665-A1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | MME, DNPEP, CMA1 | MME 1/4885ACE 4/4885MMEL1 74/4885 |
| US-10189823-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
| US-10570120-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.